Related Experiment Video
Updated: Jul 6, 2026

The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
[Hyperhomocysteinemia in children and adolescents with systemic lupus erythematosus: evolutive evaluation]
Maria Teresa R A Terreri1, Roseli Oselka Saccardo Sarni, Rogério do Prado
1Disciplina de Alergia, Imunologia Clínica e Reumatologia, Departamento de Pediatria, Universidade Federal de São Paulo, São Paulo, SP, Brazil. teterreri@terra.com.br
Insights
Elevated homocysteine persists in over a quarter of juvenile systemic lupus erythematosus (SLE) patients, indicating a potential cardiovascular disease risk. Further research into therapeutic strategies and nutritional education is recommended for these patients.
Area of Science:
- Pediatric Rheumatology
- Cardiovascular Disease Pathogenesis
- Metabolic Disorders
Context:
- Juvenile systemic lupus erythematosus (SLE) is associated with an increased risk of cardiovascular disease.
- Hyperhomocysteinemia is a known risk factor for cardiovascular disease and has been implicated in SLE pathogenesis.
- Longitudinal data on homocysteine levels in juvenile SLE patients are limited.
Purpose:
- To investigate the presence and persistence of hyperhomocysteinemia in patients with juvenile SLE.
- To assess the association of elevated homocysteine with clinical factors including renal involvement, disease activity, and nutritional status.
- To compare homocysteine levels in juvenile SLE patients with healthy controls.
Summary:
- This study followed 18 juvenile SLE patients, measuring plasma homocysteine levels twice over a median of 1.5 years.
- Five patients (27.8%) consistently showed elevated homocysteine levels.
- No significant association was found between elevated homocysteine and renal involvement, disease activity, or nutritional status in this cohort.
Impact:
- Highlights the persistence of hyperhomocysteinemia in a significant subset of juvenile SLE patients.
- Underscores the need for evaluating interventions to mitigate cardiovascular disease risk in this population.
- Suggests the importance of nutritional education and therapeutic strategies targeting homocysteine levels in juvenile SLE management.
Introduction:
One of the mechanisms implicated in the pathogenesis of coronary heart disease in patients with juvenile systemic lupus erythematosus (SLE) is the hyperhomocysteinemia. Our aim was to follow patients with juvenile SLE and to identify the presence and the persistence of hyperhomocysteinemia.
Methods:
We studied 18 patients with juvenile SLE (median age 13.5 y). A survey of demographic and clinic data was performed based on patients records. The plasma homocysteine concentration was performed twice with a median interval of 1.5 years (1.3-2.5) and association with nutritional status, disease activity, renal involvement and use of methotrexate was sought. The plasma homocysteine concentration was also evaluated in 59 healthy controls, sex and age-matched to the patients.
Results:
Of the 18 patients with juvenile SLE, 16 (88.9%) were female and 13 (72.2%) had renal involvement. Five out of 18 patients (27.8%) persisted with increased concentration of plasma homocysteine (above the 90th percentile of the healthy group). The elevated concentration of homocysteine did not show statistically significant association neither with renal involvement (in the first dosage, p=0.676 and in the second, p=0.500), disease activity (in the first dosage, p=0.630 and in the second, p=0.182), overweight/obesity (in the first dosage, p=0.485 and in the second, p=0.288) nor with short stature (in the first dosage, p=0.202 and in the second, p=0.500).
Conclusion:
This study emphasizes the persistence of elevated concentration of homocysteine in some patients with juvenile SLE and the need for evaluations of therapeutic strategies and nutritional education aiming to reduce risk factors of cardiovascular disease.
Related Concept Videos
Nephrotic Syndrome II : Assessment and Medical Management
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Pharmacokinetics in Pediatric Patients: Drug Excretion
Nephrotic Syndrome I : Introduction